FeesSafety
Pluang+

UBS and RBC maintain buy ratings on Barclays despite Q3 earnings miss

Market News
23 Oct 2026
Proactive Investors
View Source
Neutral
UBS and RBC maintain buy ratings on Barclays despite Q3 earnings miss

Barclays' third-quarter earnings fell short of expectations, with a 4% profit before tax miss driven by weaker income in trading and banking fees. Despite this, UBS and RBC Capital Markets continue to recommend buying Barclays shares, citing attractive valuation and potential for shareholder returns through dividends and buybacks. UBS lowered its price target slightly, while RBC maintained its target and expects profitability to improve through 2028. The banks highlight challenges in meeting full-year income targets but remain optimistic about the bank's long-term prospects.

Barclays' third-quarter earnings missed expectations by 4% in profit before tax, despite UBS and RBC's continued buy recommendations. For readers following the Financials sector, here is Pluang's market snapshot as of Oct 23, 2026 18:02 WIB: out of 142 priced Financials-sector US stocks, 50 rose and 84 fell. Notable movers include Blackstone Inc (BX) at USD 116.61 with a 1-day change of -1.80% and a typical hold time on Pluang of 97 days, Banco Bilbao Vizcaya Argentaria SA (BBVA) at USD 24.59 with 0% Sell / 100% Buy order activity, and Deutsche Bank AG (DB) at USD 30.94 with 0% Sell / 100% Buy order activity.

More News

Zinc and tin supply shortages revive interest in historic US mining districts with new drilling results.

Zinc and tin supply shortages revive interest in historic US mining districts with new drilling results.

Global zinc supply is expected to fall short by 88,000 tonnes in 2026 amid declining mine production, while tin demand is projected to outpace supply growth through 2035. This has renewed exploration in historic polymetallic mining districts in the U...

Market News
Bullish
19 minutes ago
Avacta's AVA6103 shows promise against Enhertu-resistant tumors in early trial and preclinical data

Avacta's AVA6103 shows promise against Enhertu-resistant tumors in early trial and preclinical data

Avacta Therapeutics presented positive preclinical and early clinical data for AVA6103, a novel peptide-drug conjugate targeting FAP-positive tumors resistant to Enhertu. AVA6103 demonstrated superior tumor control and prolonged drug release in precl...

Market News
Bullish
1 hour ago
Obra Capital closes $403.6M CLO deal, pushing total CLO issuance over $2B in under two years.

Obra Capital closes $403.6M CLO deal, pushing total CLO issuance over $2B in under two years.

Obra Capital has closed its fifth Collateralized Loan Obligation (CLO) offering, raising $403.6 million. This deal brings the firm's total CLO issuance to more than $2 billion across five deals in less than two years, demonstrating strong investor co...

Company Fundamentals
Bullish
1 hour ago
Padeliporfin VTP shows promise in making unresectable pancreatic cancer operable in Phase 1 trial

Padeliporfin VTP shows promise in making unresectable pancreatic cancer operable in Phase 1 trial

ImPact Biotech reported positive early results from its Phase 1 trial of Padeliporfin VTP in patients with locally advanced, unresectable pancreatic cancer. Of 12 patients treated, 75% have undergone or are scheduled for surgery, with over half achie...

Company Fundamentals
Bullish
1 hour ago
eSoftware offers a quick diagnostic to help organizations secure sensitive files before Microsoft 365 Copilot rollout.

eSoftware offers a quick diagnostic to help organizations secure sensitive files before Microsoft 365 Copilot rollout.

eSoftware Associates has introduced a free five-minute AI readiness assessment to help regulated organizations identify and prioritize security risks related to sensitive file access in Microsoft 365 before deploying Copilot. The assessment highlight...

Others
Neutral
2 hours ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App